Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II dose-escalation and expansion study of ZG005 in advanced solid tumors
CTR20220021Phase 2Completed
- Sponsor
- Zelgen
- Start
- Jun 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in Nonhematologic neoplasms, small cell lung cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC), Cervical Cancer (CC), neuroendocrine carcinoma (NEC), sponsored by Zelgen. Started Jun 2022; status: completed.
02
Drugs
nilvanstomig
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)Esophageal Squamous Cell Carcinoma (ESCC)Cervical Cancer (CC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20220021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220021.